S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AxoGen, Inc. stock logo
AXGN
AxoGen
$6.50
-0.8%
$8.61
$3.45
$10.83
$286.16M1.03416,935 shs332,067 shs
InMode Ltd. stock logo
INMD
InMode
$17.41
+0.4%
$20.99
$16.96
$48.25
$1.46B2.161.60 million shs1.93 million shs
Natus Medical Incorporated stock logo
NTUS
Natus Medical
$32.96
$32.96
$20.90
$33.93
$1.14B0.22325,002 shs1,514 shs
NxStage Medical, Inc. stock logo
NXTM
NxStage Medical
$30.00
$30.00
$23.17
$30.00
$2.00B0.251.51 million shs2.61 million shs
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AxoGen, Inc. stock logo
AXGN
AxoGen
-5.62%-10.76%-14.71%-25.40%-35.15%
InMode Ltd. stock logo
INMD
InMode
-0.63%-6.12%-15.78%-23.24%-52.88%
Natus Medical Incorporated stock logo
NTUS
Natus Medical
0.00%0.00%0.00%0.00%0.00%
NxStage Medical, Inc. stock logo
NXTM
NxStage Medical
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AxoGen, Inc. stock logo
AXGN
AxoGen
1.7052 of 5 stars
3.53.00.00.00.02.50.6
InMode Ltd. stock logo
INMD
InMode
3.1061 of 5 stars
3.23.00.00.02.31.72.5
Natus Medical Incorporated stock logo
NTUS
Natus Medical
N/AN/AN/AN/AN/AN/AN/AN/A
NxStage Medical, Inc. stock logo
NXTM
NxStage Medical
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AxoGen, Inc. stock logo
AXGN
AxoGen
3.00
Buy$10.6764.10% Upside
InMode Ltd. stock logo
INMD
InMode
2.33
Hold$32.8088.40% Upside
Natus Medical Incorporated stock logo
NTUS
Natus Medical
N/AN/AN/AN/A
NxStage Medical, Inc. stock logo
NXTM
NxStage Medical
N/AN/AN/AN/A

Current Analyst Ratings

Latest NXTM, INMD, NTUS, and AXGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/12/2024
InMode Ltd. stock logo
INMD
InMode
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$34.00 ➝ $33.00
4/9/2024
InMode Ltd. stock logo
INMD
InMode
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
2/15/2024
InMode Ltd. stock logo
INMD
InMode
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$32.00 ➝ $34.00
2/14/2024
InMode Ltd. stock logo
INMD
InMode
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$24.00 ➝ $26.00
1/19/2024
AxoGen, Inc. stock logo
AXGN
AxoGen
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$12.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AxoGen, Inc. stock logo
AXGN
AxoGen
$159.01M1.79N/AN/A$2.22 per share2.93
InMode Ltd. stock logo
INMD
InMode
$492.05M2.97$2.21 per share7.89$6.68 per share2.61
Natus Medical Incorporated stock logo
NTUS
Natus Medical
$473.44M2.41$2.02 per share16.34$12.44 per share2.65
NxStage Medical, Inc. stock logo
NXTM
NxStage Medical
$393.94M5.08$0.29 per share103.07$3.22 per share9.32

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AxoGen, Inc. stock logo
AXGN
AxoGen
-$21.72M-$0.52N/AN/AN/A-13.66%-22.38%-11.24%5/2/2024 (Confirmed)
InMode Ltd. stock logo
INMD
InMode
$197.92M$2.307.577.91N/A40.22%29.80%27.02%5/2/2024 (Confirmed)
Natus Medical Incorporated stock logo
NTUS
Natus Medical
$13.18M$0.3789.0820.99N/A2.65%10.15%7.65%N/A
NxStage Medical, Inc. stock logo
NXTM
NxStage Medical
-$14.47M-$0.22N/A136.36N/A-1.29%-2.50%-1.60%N/A

Latest NXTM, INMD, NTUS, and AXGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
AxoGen, Inc. stock logo
AXGN
AxoGen
-$0.10N/A+$0.10N/AN/AN/A  
5/2/2024N/A
InMode Ltd. stock logo
INMD
InMode
$0.40N/A-$0.40N/AN/AN/A  
3/5/2024Q4 2023
AxoGen, Inc. stock logo
AXGN
AxoGen
-$0.20-$0.09+$0.11-$0.09$42.70 million$42.92 million
2/13/202412/31/2023
InMode Ltd. stock logo
INMD
InMode
$0.66$0.71+$0.05$0.64$124.77 million$126.80 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AxoGen, Inc. stock logo
AXGN
AxoGen
N/AN/AN/AN/AN/A
InMode Ltd. stock logo
INMD
InMode
N/AN/AN/AN/AN/A
Natus Medical Incorporated stock logo
NTUS
Natus Medical
N/AN/AN/AN/AN/A
NxStage Medical, Inc. stock logo
NXTM
NxStage Medical
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AxoGen, Inc. stock logo
AXGN
AxoGen
0.71
2.89
2.14
InMode Ltd. stock logo
INMD
InMode
N/A
12.51
11.87
Natus Medical Incorporated stock logo
NTUS
Natus Medical
N/A
2.54
1.90
NxStage Medical, Inc. stock logo
NXTM
NxStage Medical
N/A
3.60
2.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
80.29%
InMode Ltd. stock logo
INMD
InMode
68.04%
Natus Medical Incorporated stock logo
NTUS
Natus Medical
92.35%
NxStage Medical, Inc. stock logo
NXTM
NxStage Medical
80.34%

Insider Ownership

CompanyInsider Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
7.21%
InMode Ltd. stock logo
INMD
InMode
6.92%
Natus Medical Incorporated stock logo
NTUS
Natus Medical
1.20%
NxStage Medical, Inc. stock logo
NXTM
NxStage Medical
4.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AxoGen, Inc. stock logo
AXGN
AxoGen
42643.69 million40.54 millionOptionable
InMode Ltd. stock logo
INMD
InMode
58183.98 million78.17 millionOptionable
Natus Medical Incorporated stock logo
NTUS
Natus Medical
1,40034.58 million34.17 millionOptionable
NxStage Medical, Inc. stock logo
NXTM
NxStage Medical
N/A66.68 millionN/AOptionable

NXTM, INMD, NTUS, and AXGN Headlines

SourceHeadline
Army Medicine NewsArmy Medicine News
army.mil - March 6 at 4:10 PM
Nextcom Ltd.Nextcom Ltd.
wsj.com - July 21 at 6:09 PM
Stunning Consequences of Thrice-Weekly In-center DialysisStunning Consequences of Thrice-Weekly In-center Dialysis
medscape.com - April 19 at 2:33 PM
Medical Affairs TeamMedical Affairs Team
medicalnewstoday.com - December 23 at 12:43 AM
NXTM.TA - Nextcom Ltd. | Stock Price & Latest News | ReutersNXTM.TA - Nextcom Ltd. | Stock Price & Latest News | Reuters
reuters.com - September 23 at 8:17 AM
Fresenius’ NxStage launches Speedswap for critical care dialysisFresenius’ NxStage launches Speedswap for critical care dialysis
massdevice.com - August 25 at 4:39 PM
Omnicell to Buy Ateb, Expand in Adherence Tools MarketOmnicell to Buy Ateb, Expand in Adherence Tools Market
finance.yahoo.com - October 26 at 1:32 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AxoGen logo

AxoGen

NASDAQ:AXGN
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
InMode logo

InMode

NASDAQ:INMD
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.
Natus Medical logo

Natus Medical

NASDAQ:NTUS
Natus Medical Incorporated provides medical device solutions focuses on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and technologies used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing assessment, screening, and instrument fitting solutions; jaundice management products; brain injury products; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. Additionally, it offers essential products used in the everyday operation of neonatal intensive care unit (NICU); balance assessment systems to evaluate patients with balance disorders; and NICVIEW, a live streaming video for families with babies in the NICU. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation for hearing and balance care professionals. It serves university medical centers, public and private hospitals, physician offices, clinics, research laboratories, and others. The company was formerly known as ALGOTEK Instruments, Inc. and changed its name to Natus Medical Incorporated in September 1988. Natus Medical Incorporated was incorporated in 1987 and is headquartered in Middleton, Wisconsin.
NxStage Medical logo

NxStage Medical

NASDAQ:NXTM
NxStage Medical, Inc., a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting. The company operates through three segments: System One, In-Center, and Services. The System One segment sells and rents the NxStage System One and PureFlow SL dialysate preparation equipment, as well as sells disposable products in the home and critical care market for the treatment of end-stage renal disease (ESRD) patients in the home or a home-like setting and in the critical care market for the treatment of hospital-based patients with acute kidney failure or fluid overload. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers, and needles for apheresis. The Services segment offers dialysis services to patients at NxStage Kidney Care dialysis centers. As of February 3, 2018, it had 21 centers. NxStage Medical, Inc. markets its products through direct sales to dialysis clinics and hospitals in the United States, the United Kingdom, and Canada, as well as through distributors in Europe and internationally. The company was formerly known as QB Medical, Inc. and changed its name to NxStage Medical, Inc. NxStage Medical, Inc. was founded in 1998 and is headquartered in Lawrence, Massachusetts.